Oncology Care Model Measure Specifications

OCM-8 NQF 0223 Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer

Note: This specification should be used for submitting data through the data registry

SUMMARY OF CHANGES FROM NQF 0223 SPECIFICATIONS

- Timing added: Primary tumors of the colon must occur within 12 months before the end of the measurement period.
- Timing added: The clinical trial must overlap the measurement period.
- Timing added: Chemotherapy must be recommended and not received within 4 months (120 days) of diagnosis.

Description

Percentage of patients under the age of 80 with AJCC III (lymph node positive) colon cancer for whom adjuvant chemotherapy is recommended and not received or administered within 4 months (120 days) of diagnosis.

Measure Scoring

Proportion

Measure Type

Process

Improvement Notation

Higher score indicates better quality

Definitions

Not Applicable

Guidance

This measure is to be reported once per reporting period for qualifying patients.

For aggregate level reporting, practices are required to report on patients where the qualifying cancer diagnosis starts within 210 days before the end of the reporting period. The 210 days allows time for the practice to meet the 120 days numerator compliance window when a patient is diagnosed in the last month of a reporting period.

Where available, FORDS equivalent NAACCR Items have been provided in the step instructions of the supplemental data elements and each population.
# Oncology Care Model Measure Specifications

Chemotherapy recommended and not received:
1. Not recommended/administered because it was contraindicated due to patient risk factors.
2. Not administered because the patient died prior to planned or recommended therapy.
3. It was recommended by the patient’s physician but was not administered as part of the first course of therapy. No reason was stated in the patient record.
4. It was recommended by the patient’s physician but refused by the patient, patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.

## Supplemental Data Elements

For every patient evaluated by this measure also identify gender

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>For every patient evaluated by this measure identify gender</td>
<td>• Gender</td>
<td>• OCM Gender OR • NAACCR Item 220</td>
</tr>
<tr>
<td></td>
<td>(FORDS equivalent: NAACCR Item # 220)</td>
<td>• NAACCR Item 220</td>
<td></td>
</tr>
</tbody>
</table>

## Initial Population

Not Applicable

## Denominator

Include, if all of the following characteristics are identified:

- Age 18-79 years at time of cancer diagnosis
- Known or assumed to be first or only cancer diagnosis
- Primary tumors of the colon within 12 months before the end of the measurement period
- Colon Cancer treated surgically
- Epithelial invasive malignancy only
- At least one pathologically examined regional lymph node positive for cancer (AJCC Stage III)
- All or part of first course of treatment coordinated by the reporting practice

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>Age $\geq$ 18 year(s) at time of colon cancer diagnosis AND Age $\leq$ 79 year(s) at time of colon cancer diagnosis (FORDS equivalent: NAACCR Item # 230)</td>
<td>• Birthdate • Colon Cancer Diagnosis • Colon Cancer Diagnosis Start Date • Measurement Period End Date</td>
<td>• OCM Colon Cancer Diagnosis OR • NAACCR Item 230 • NAACCR Item 400 • NAACCR Item 390</td>
</tr>
<tr>
<td>Step(s)</td>
<td>Instructions</td>
<td>Data Element(s)</td>
<td>OCM Code Set(s)</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| **Step 1 cont’d** | Primary tumors of the colon within 12 months before the end of the measurement period:  
NAACCR Item # 400  
NAACCR Item # 390 | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Other Cancer Diagnosis  
• Other Cancer Diagnosis Start Date  
• NAACCR Item 560 | • OCM Colon Cancer Diagnosis  
• OCM 8 Other Cancer Diagnosis  
OR  
• NAACCR Item 560 |
| **Step 2**       | First or only cancer diagnosis  
(FORDS equivalent:  
NAACCR Item # 560) | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Other Cancer Diagnosis  
• Other Cancer Diagnosis Start Date  
• NAACCR Item 560 | • OCM Colon Cancer Diagnosis  
• OCM 8 Other Cancer Diagnosis  
OR  
• NAACCR Item 560 |
| **Step 3**       | Surgical treatment of the primary colon cancer site  
(FORDS equivalent:  
NAACCR Item # 1290) | • Colon Cancer Surgery  
• Colon Cancer Surgery Date  
• NAACCR Item 1290 | • OCM Colon Cancer Surgery  
OR  
• NAACCR Item 1290 |
| **Step 4**       | Epithelial invasive malignancy only  
(FORDS equivalent:  
NAACCR Item # 522) | • Epithelial Malignancy  
• NAACCR Item 522 | • OCM 8 Epithelial Malignancy  
OR  
• NAACCR Item 522 |
| **Step 5**       | Behavior Code=Invasive:  
NAACCR Item # 523 | • NAACCR Item 523 | • NAACCR Item 523 |
| **Step 6**       | At least one regional lymph node positive for cancer (AJCC Stage III)  
(FORDS equivalent:  
NAACCR Item # 820) | • Pathology Evaluation  
• Pathology Evaluation Result  
• NAACCR Item 820 | • OCM Pathology Evaluation  
• OCM 8 Pathology Evaluation Stage III Results  
Valid TNM Combinations:  
T1,N1,M0  
T2,N1,M0  
T1,N2a,M0  
T3,N1,M0  
T4a,N1,M0  
T2,N2a,M0  
T3,N2a,M0  
T4a,N2a,M0  
T1,N2b,M0  
T2,N2b,M0  
T3,N2b,M0  
T4a,N2b,M0  
T4b,N1,M0  
T4b,N2,M0  
OR  
• NAACCR Item 820 |
| **Step 7**       | All or part of first course of treatment coordinated by the reporting practice:  
NAACCR Item # 610 | • NAACCR Item 610 | • NAACCR Item 610 |
## Oncology Care Model Measure Specifications

### Denominator Exclusions
Exclude, if any of the following characteristics are identified:
- In situ or metastatic disease (AJCC Stage IV)
- Patient died within 4 months (120 days) of diagnosis
- Patient participating in clinical trial which directly impacts receipt of standard of care after the colon cancer diagnosis

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td>One of the following options:</td>
<td></td>
<td>One of the following options:</td>
</tr>
<tr>
<td>1.</td>
<td>Metastatic Disease (AJCC Stage IV):</td>
<td>- Colon Cancer Diagnosis</td>
<td>1.</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 910 Metastatic OR</td>
<td>- Colon Cancer Diagnosis Start Date</td>
<td>1. NAACCR Item 910 Metastatic</td>
</tr>
<tr>
<td>2.</td>
<td>Clinical M or Pathologic M:</td>
<td>- Deceased</td>
<td>NAACCR Item 970 Metastatic</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 900 or 960</td>
<td>- Deceased Date</td>
<td>2.</td>
</tr>
<tr>
<td>3.</td>
<td>In situ Disease:</td>
<td>- Clinical Trial Participant</td>
<td>NAACCR Item 900</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 910 In Situ OR</td>
<td>- Clinical Trial Participant Start Date</td>
<td>NAACCR Item 960</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 970 In Situ</td>
<td>- Clinical Trial Participant End Date</td>
<td>3.</td>
</tr>
<tr>
<td>4.</td>
<td>Expired within 4 months (120 days) of colon cancer diagnosis</td>
<td>- Measurement Period Start Date</td>
<td>NAACCR Item 910 In Situ</td>
</tr>
<tr>
<td></td>
<td>(FORDS equivalent: NAACCR Item # 1750 &lt;120 days of diagnosis [NAACCR Item # 390] AND NAACCR Item # 1760)</td>
<td>- Measurement Period End Date</td>
<td>NAACCR Item 970 In Situ</td>
</tr>
<tr>
<td>5.</td>
<td>Participating in clinical trial for colon cancer impacting treatment overlaps measurement period (this is a manual exclusion step and not identified as a NAACCR item)</td>
<td>- NAACCR Item 910 Metastatic</td>
<td>4.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 970 Metastatic</td>
<td>OCM Deceased</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 910 In Situ</td>
<td>OCM Colon Cancer Diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 970 In Situ</td>
<td>OCM Colon Cancer Diagnosis Start Date</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 1750</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 1760</td>
<td>NAACCR Item 1750</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 390</td>
<td>NAACCR Item 390</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- NAACCR Item 1760</td>
<td>NAACCR Item 1760</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- OCM Deceased</td>
<td>5.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- OCM Colon Cancer Diagnosis</td>
<td>OCM Clinical Trial Participant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- OCM Colon Cancer Diagnosis Start Date</td>
<td>OCM Clinical Trial Participant Start Date</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- OCM Clinical Trial Participant End Date</td>
<td>OCM Clinical Trial Participant End Date</td>
</tr>
</tbody>
</table>
Oncology Care Model Measure Specifications

**Numerator**
Chemotherapy is administered within 4 months (120 days) of diagnosis or it is recommended and not received within 4 months (120 days) of diagnosis

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | One of the following options: 1. Chemotherapy is administered within 4 months (120 days) of diagnosis  
(All of the following FORDS equivalent:  
- NAACCR Item # 1390 Administered  
- NAACCR Item # 1220  
- NAACCR Item # 390)  
2. Chemotherapy is recommended and not received within 4 months (120 days) of diagnosis  
(Both of the following FORDS equivalent:  
- NAACCR Item # 1390 Recommended  
- NAACCR Item # 390) | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Chemotherapy  
• Chemotherapy Start Date  
• Chemotherapy Recommended  
• Chemotherapy Recommended Start Date  
• NAACCR Item 1390 Administered  
• NAACCR Item 1390 Recommended  
• NAACCR Item 1220  
• NAACCR Item 390 | • OCM Colon Cancer Diagnosis  
• OCM 8 Chemotherapy  
• OCM Chemotherapy Recommended OR  
• NAACCR Item 1390 Administered  
• NAACCR Item 1390 Recommended  
• NAACCR Item 1220  
• NAACCR Item 390 |

**Denominator Exceptions**
Not Applicable

**Numerator Exclusions**
Not Applicable

**Risk Adjustment**
None

**Rationale**
Improved survival for patients with Stage III lymph node positive colon cancer

**Clinical Recommendation Statements**
Not Applicable
Oncology Care Model Measure Specifications

References


